The association between bone mineral density (BMD) and serum25-hydroxyvitamin D (25(OH) D) concentration is weak, particularly in certain races (eg, BlackAfrican vs Caucasian) and in athletic populations. We aimed to examine if bioavailable vitamin D rather than serum 25(OH)D was related to markers of bone health within a racially diverse athletic population. Methods In 604 male athletes (Arab (n=327), Asian (n=48), Black (n=108), Caucasian (n=53) and Hispanic (n=68) 
AbsTrACT background
The association between bone mineral density (BMD) and serum25-hydroxyvitamin D (25(OH) D) concentration is weak, particularly in certain races (eg, BlackAfrican vs Caucasian) and in athletic populations. We aimed to examine if bioavailable vitamin D rather than serum 25(OH)D was related to markers of bone health within a racially diverse athletic population. Methods In 604 male athletes (Arab (n=327), Asian (n=48), Black (n=108), Caucasian (n=53) and Hispanic (n=68)), we measured total 25 
InTrOduCTIOn
Vitamin D 3 (cholecalciferol) is a lipophilic prohormone produced in the skin from exposure to sunlight. Cholecalciferol is transported bound to vitamin D-binding protein (DBP) and is hydroxylated in the liver to form 25-hydroxyvitamin D (25(OH)D). 25(OH)D undergoes further hydroxylation in the kidney to form the active hormone 1,25-dihydroxyvitamin D (1,25(OH) 2 D). This bioactive metabolite regulates intestinal calcium absorption, bone calcium resorption and renal calcium reabsorption to maintain calcium homeostasis and promote skeletal mineralisation. 1 2 Accordingly, skeletal pathologies such as rickets and osteomalacia often present when 25(OH)D levels are consistently deficient. 3 Clinically to date, measuring serum 25(OH)D concentration provides the best estimate of vitamin D status as both circulating levels of cholecalciferol and 1,25(OH) 2 D have short half-lives, approximately 24 hours and 4-6 hours, respectively. 4 5 Serum cholecalciferol levels can also be affected by recent sunlight exposure and is difficult to measure due to the lipophilic nature of the molecule. Optimum concentrations of serum 25(OH)D for skeletal health are still debated. 6 Many clinicians define vitamin D sufficiency as the lowest serum 25(OH)D concentration that maximally suppresses parathyroid hormone (PTH) secretion and/or optimises bone mineral density (BMD). [6] [7] [8] The generally accepted serum 25(OH)D concentration ranges are: severely deficient (<10 ng/mL), deficient (10-20 ng/mL), insufficient (20-30 ng/mL) or sufficient (>30 ng/mL), although of evidence supporting these categories are derived from elderly cohorts or groups with existing skeletal disorders. [9] [10] [11] [12] Association between BMD and serum 25(OH) D concentration is weak. [13] [14] [15] [16] [17] Our group previously demonstrated no association between serum 25(OH)D and markers of bone health in weight bearing athletes of different racial background, suggesting that markers of bone health are independent of serum 25(OH)D concentrations. 18 It appears there is a 'paradoxical relationship' between race and vitamin D concentration that has largely been ignored, that is, Black individuals generally have the lowest serum 25(OH)D concentrations but the greatest BMD and reduced risk of fracture. 14 19 DBP may provide an insight as to why certain racial groups have distinct 25(OH)D and BMD relationships. 20 DBP is the primary vitamin D carrier, binding 85%-90% of total circulating 25(OH)D, with the remaining unbound 25(OH) D considered to be bioavailable. 21 Polymorphisms in the DBP coding genes (specifically rs4588 and rs7041) produce proteins that differ in affinity for 25(OH)D, and it is these polymorphisms that are known to differ between racial groups. 22 Differentiating between total vitamin D (measured as 25(OH) D) and bioavailable vitamin D is crucial, given that the latest evidence suggests that DBP inhibits certain actions of vitamin D, since the bound fraction is unavailable to act on target cells. 20 21 23 Consequently, serum bioavailable vitamin D may have a better association with bone health than serum 25(OH)D concentration. 20 To date, research on vitamin D status in athletes has focused solely on serum 25(OH)D and as a consequence, the current advice and guidelines given to athletes and clinicians treating vitamin D deficiency may be inaccurate. Therefore, the present study set out
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to examine if bioavailable vitamin D is related to markers of bone health within a racially diverse athletic population. It was hypothesised that bioavailable vitamin D and not serum vitamin D would be associated with markers of bone health in a racially diverse athlete population.
MeThOds Participants
Six hundred and four male athletes registered with the Qatar Olympic Committee (QOC) (Arab (n=327), Asian (n=48), Black (n=108), Caucasian (n=53) and Hispanic (n=68)), exercising ≥6 hours/week, presented for precompetition medical assessment at Aspetar Sports Medicine Hospital, Qatar. All athletes undertook dual-energy X-ray absorptiometry for assessment of their BMD and a blood test to assess serum 25(OH)D concentration and DBP. No athlete was taking vitamin D supplementation on recruitment. Ethical approval was obtained from Qatar Anti-Doping Laboratory IRB (#F2014000062).
Laboratory analyses Serum 25(OH)D and PTH
Venous blood samples were collected from athletes following an overnight fast. The blood sample was separated into two aliquots (5 mL SST tubes) of serum for analysis of 25(OH)D and one aliquot of plasma for PTH assessment. Samples were centrifuged for 10 min at 3000 RPM. Serum 25(OH)D was analysed using chemiluminescent immunoassay technology with sensitivity set at 7 ng/mL (Liaison 25-OH Vitamin-D Total Assay; Diasorin, Saluggia (Vercelli), Italy). The intra-assay and interassay CV was 7.6%-9.4% and 9.8%-13.4%, respectively. Based on the serum 25(OH)D results, athletes were placed into four 25(OH)D categories: severely deficient (<10 ng/mL), deficient (10-20 ng/mL), insufficient (20-30 ng/mL) or sufficient (>30 ng/mL). Levels of intact PTH were measured with the use of the DiaSorin Liaison analyser, chemiluminescence immunoassay (CLIA). The interassay CV was 2.5%.
Vitamin d-binding protein
Serum DBP concentrations (µg/mL) were determined using a commercially available kit (R&D Systems, UK). The limit of sensitivity was ≤0.65 ng/mL and an interassay coefficient of variation was 7.2%. An automatic ELISA microplate reader (Infinite200-PRO NanoQuant, Switzerland) and computer software Magellan Standard (V.7.1) were used to analyse DBP.
Assessment of bMd
Dual-energy x-ray absorptiometry (Osteocore III, Perols, France, v5.22b) scanning was used to assess hip, femoral neck and lumbar spine BMD. A certified technologist from the International Society of Clinical Densitometry performed all calibrations and measurements. Quality assurance was performed each morning before testing. The coefficient of variation for these records is <1.01% in Aspetar. BMD was calculated in g/cm 2 for spine (L2-L4), hip-neck and hip-total. In addition, the clinical age-matched and gender-specific Z-score index was used to classify the BMD. T-scores were calculated for those athletes older than 20 years as per WHO recommendations. 24 
Calculation of bioavailable 25(Oh)d
Bioavailable and DBP-bound 25(OH)D were calculated using equations from material provided by ref 20 and adapted from those described by Vermeulen and colleagues. 25 These methods use the free hormone hypothesis to define bioavailable hormone, as the fraction that is both free and albumin bound, that is, the fraction not bound to circulating binding proteins such as DBP. Free levels of 25(OH)D were calculated using the following equation:
After calculating free 25(OH)D, we used equation 2 to calculate the concentration of bioavailable (non-DBP bound vitamin): 
dIsCussIOn
The aim of the present study was to examine if bioavailable vitamin D was related to markers of bone health within a racially diverse athlete population. It was observed that after adjusting for age and race, bioavailable vitamin D was closely associated with BMD (spine, neck and hip), while there was no association between serum 25(OH)D concentration and BMD at any site. DBP was positively associated with neck and hip T-scores but not spine. Serum 25(OH)D and bioavailable 25(OH)D were not associated with T-scores at any site. Furthermore, mean serum DBP concentrations were not associated with 25(OH) D concentrations. For clinicians treating vitamin D insufficiency based on serum 25(OH)D measures, our data suggest that the current choice of assay is not fit for practice when examining the relationship between bone health and vitamin D concentrations.
The role of bioavailable vitamin d on markers of bone health
Vitamin D is just one of many factors including energy availability and weight bearing exercise that can impact on bone health. The role of vitamin D and calcium in bone development, growth and integrity have been well documented.
1 Previous studies, however, demonstrate inconsistent associations between serum 25(OH)D concentrations and BMD in general 16 17 and athletic populations. 26 It has been postulated that the osteogenic effect of weight-bearing exercise (ie, loading the bones) may be sufficient to maintain markers of bone health, irrespective of 25(OH)D status in healthy adults. 27 28 Though the present data also suggest that the clinical utilisation of serum 25(OH) D could be an additional factor for this inconsistency, given that bioavailable vitamin D and not serum 25(OH)D was associated with BMD at all sites in an racially diverse athletic population. Using the free hormone hypothesis, the unbound fraction (or bioavailable vitamin D) may exert a stronger biological effect on BMD than total 25(OH)D. 21 23 Since serum 25(OH)D is generally used in previous observational and interventional studies, it may explain such inconsistencies in the poor association between serum 25(OH)D and BMD. 29 30 Accordingly, our data support the notion that current 25(OH)D reference ranges provide an inaccurate representation of true vitamin D status in athletes. In contrast to previous findings, DBP concentration was not associated with 25(OH)D concentrations (p=0.392). 29 While there was a positive linear association between 25(OH)D status and bioavailable vitamin D, PTH levels were not associated with 25(OH)D levels, BMD or T-scores, suggesting that the association between bioavailable 25(OH)D levels and BMD is not mediated via PTH.
Impact of race
Studies support that racial differences or a 'paradox' exists in the relationship between serum 25(OH)D concentrations and markers of bone health. 14 31 32 Specifically, recent studies in the general population have demonstrated that polymorphisms in the DBP gene were associated with corresponding changes in total 25(OH)D levels and the risk of osteoporosis. 22 33 Aggarwal et al demonstrated that bioavailable 25(OH)D was a better measure of vitamin D status with respect of BMD in patients with nephrotic syndrome. 34 To our knowledge, this is the first study to examine DBP and bioavailable vitamin D alongside bone health as assessed by DXA in athletes. Our data support these previous observations, with Hispanic athletes presenting with greater mean serum 25(OH)D levels (32.1 ng/mL) compared with Caucasian (26.2 ng/mL) and Black (19.9 ng/mL) athletes, despite no difference in bioavailable vitamin D or BMD at any site. Bioavailable vitamin D is determined by DBP concentration, which is encoded by the group-specific component (GC) gene. 35 Polymorphisms in the GC gene produce proteins that differ in affinity for 25(OH)D, and it is these polymorphisms that are known to differ between racial groups. Racial differences in the prevalence of common genetic polymorphisms provide a likely Table 3 Parameter estimates (β 95% CI) of association of log transformed vitamin D parameters against independent bone health variables (spine, neck and hip BMD and T-scores) after adjusting for age and race explanation for this observation. Consequently, our data have implications for the wider general population, with further research warranted an adolescent and female athletes. 
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Limitations
The primary limitations of this study are the lack of data on DBP polymorphisms across racial groups and the cross-sectional design. The equations used to calculate free and bioavailable 25(OH)D in this study used the affinity constants of the Gc1F allele, as did the equations in Powe et al. 29 While we acknowledge that training volume and intensity were not recorded, athletes were only included in the study if they were registered with the QOC, competed at national or international level and trained for more than 6 hours per week. We also acknowledge that serum 25(OH)D measurement only offered a snapshot of current status. Thus, it is entirely possible for severely deficient (<10 ng/mL) and deficient (10-20 ng/mL) athletes in the present study to have spent many years sufficient (>30 ng/mL) prior to recruitment. An additional limitation is that only male athletes were studied, due to a lack of female athletes presenting for precompetition medical assessment at the time of data analysis. Finally, the impact of training load and dietary intake data, to assess total energy and calcium intake, and the assessment of steroid hormones were not accounted for in this study. Although our previous research reports no association between 25(OH) D and bone health, 26 future longitudinal trials including genotype-specific binding affinity constants in the calculation for bioavailable vitamin D, training, dietary and hormone analysis in racially diverse populations are warranted.
COnCLusIOn
In conclusion, regardless of age or race, bioavailable vitamin D and not serum 25(OH)D was associated with BMD in a racially diverse athletic population. Our data question the value of routine 25(OH)D screening in athletes, since all athletes in the present study demonstrated clinically normal bone health, despite 85% of athletes presenting with either serum 25(OH) D insufficiency, deficiency or severe deficiency, respectively. This study suggests that bioavailable vitamin D, rather than the current standard of 25(OH)D, is a better measure of vitamin D status with respect to BMD.
What are the findings?
► This study demonstrated that in a racially diverse athletic population, bioavailable vitamin D was closely associated with bone mineral density (BMD; spine, neck and hip Targeted vitamin D screening and supplementation should be reserved for those athletes presenting with relative energy deficiency syndrome or those competing in non-weight bearing sports, such as cycling and swimming, where the osteogenic effect of bone loading is sub-optimal.
